Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INDVNASDAQ:IRONNASDAQ:PRTCNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINDVIndivior$12.72+2.5%$10.49$7.33▼$18.50$1.77B0.981.05 million shs2.16 million shsIRONDisc Medicine$46.76-0.2%$45.07$30.82▼$68.73$1.62B0.77346,748 shs437,325 shsPRTCPureTech Health$18.51+0.8%$17.25$13.30▼$31.00$442.67M1.144,707 shs1,153 shsVERAVera Therapeutics$19.02-4.6%$21.94$18.53▼$51.61$1.27B1.28795,191 shs2.15 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINDVIndivior0.00%+12.97%+10.13%+37.66%-29.49%IRONDisc Medicine0.00%-1.29%-5.88%-16.77%+36.97%PRTCPureTech Health0.00%+1.70%+4.81%-0.27%-36.72%VERAVera Therapeutics0.00%-3.16%-19.92%-36.45%-48.76%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINDVIndivior2.4971 of 5 stars2.63.00.00.02.41.71.9IRONDisc Medicine2.208 of 5 stars3.51.00.00.03.52.50.0PRTCPureTech Health2.422 of 5 stars3.85.00.00.02.20.00.0VERAVera Therapeutics2.0763 of 5 stars3.61.00.00.03.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINDVIndivior 3.25Buy$15.0017.92% UpsideIRONDisc Medicine 3.09Buy$98.80111.29% UpsidePRTCPureTech Health 3.50Strong Buy$45.00143.11% UpsideVERAVera Therapeutics 3.10Buy$63.33232.98% UpsideCurrent Analyst Ratings BreakdownLatest PRTC, IRON, INDV, and VERA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025IRONDisc MedicineBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$112.00 ➝ $120.005/7/2025VERAVera TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$34.00 ➝ $26.005/7/2025VERAVera TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$107.00 ➝ $100.005/5/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$75.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/6/2025INDVIndiviorPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $13.003/4/2025VERAVera TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$77.00 ➝ $71.003/3/2025IRONDisc MedicineScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$73.00 ➝ $75.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINDVIndivior$1.17B1.50$2.57 per share4.94N/A∞IRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/APRTCPureTech Health$4.32M103.03N/AN/A$16.94 per share1.09VERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINDVIndivior$2M-$0.31N/A7.44N/A-3.96%-241.73%15.09%7/24/2025 (Estimated)IRONDisc Medicine-$76.43M-$3.92N/AN/AN/AN/A-25.24%-23.96%8/6/2025 (Estimated)PRTCPureTech Health-$65.70MN/A0.00N/AN/AN/AN/AN/AN/AVERAVera Therapeutics-$95.99M-$3.00N/AN/AN/AN/A-50.13%-39.50%8/14/2025 (Estimated)Latest PRTC, IRON, INDV, and VERA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A5/7/2025Q1 2025IRONDisc Medicine-$0.99-$1.02-$0.03-$1.02N/AN/A4/24/2025Q1 2025INDVIndivior$0.22$0.41+$0.19$0.38$240.13 million$266.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINDVIndiviorN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINDVIndiviorN/A0.830.65IRONDisc MedicineN/A19.3619.36PRTCPureTech HealthN/A3.68N/AVERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINDVIndivior60.33%IRONDisc Medicine83.70%PRTCPureTech Health0.04%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipINDVIndiviorN/AIRONDisc Medicine4.24%PRTCPureTech Health5.30%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINDVIndivior1,164137.88 millionN/ANot OptionableIRONDisc Medicine3034.63 million28.50 millionNot OptionablePRTCPureTech Health10024.02 million22.67 millionNot OptionableVERAVera Therapeutics4063.77 million49.58 millionOptionablePRTC, IRON, INDV, and VERA HeadlinesRecent News About These CompaniesMillennium Management LLC Trims Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)June 1 at 3:44 AM | marketbeat.comVera Therapeutics (NASDAQ:VERA) Stock Price Up 5.7% - Time to Buy?May 30 at 2:08 PM | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Receives $63.33 Consensus PT from AnalystsMay 29 at 1:43 AM | americanbankingnews.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Average Rating of "Buy" by AnalystsMay 27, 2025 | marketbeat.comCantor Fitzgerald maintains Vera Therapeutics at OverweightMay 26, 2025 | uk.investing.comBNP Paribas Financial Markets Purchases Shares of 24,374 Vera Therapeutics, Inc. (NASDAQ:VERA)May 23, 2025 | marketbeat.comWoodline Partners LP Acquires 201,573 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 22, 2025 | marketbeat.comMarker Therapeutics CEO Dr. Juan Vera to Join Expert Panel Discussing CD19 CAR-T Therapy at Upcoming WebcastMay 21, 2025 | nasdaq.comVestal Point Capital LP Acquires Shares of 1,075,000 Vera Therapeutics, Inc. (NASDAQ:VERA)May 21, 2025 | marketbeat.comThornburg Investment Management Inc. Acquires 28,124 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)May 21, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Point72 Asset Management L.P.May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Decreases Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)May 21, 2025 | marketbeat.comMPM Bioimpact LLC Acquires New Position in Vera Therapeutics, Inc. (NASDAQ:VERA)May 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Acquired by Paradigm Biocapital Advisors LPMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Nicholas Investment Partners LPMay 16, 2025 | marketbeat.comEquities Analysts Offer Predictions for VERA FY2025 EarningsMay 16, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Holdings Raised by Deutsche Bank AGMay 16, 2025 | marketbeat.comNorthern Trust Corp Has $19.24 Million Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)May 16, 2025 | marketbeat.comVera Therapeutics: Huge Catalyst Upcoming For Kidney Disease DrugMay 15, 2025 | seekingalpha.comVera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Stock Position Boosted by Integral Health Asset Management LLCMay 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePRTC, IRON, INDV, and VERA Company DescriptionsIndivior NASDAQ:INDV$12.72 +0.31 (+2.50%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$12.86 +0.14 (+1.06%) As of 05/30/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Disc Medicine NASDAQ:IRON$46.76 -0.11 (-0.23%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$46.64 -0.12 (-0.25%) As of 05/30/2025 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.PureTech Health NASDAQ:PRTC$18.51 +0.15 (+0.82%) As of 05/30/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Vera Therapeutics NASDAQ:VERA$19.02 -0.91 (-4.57%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$19.05 +0.03 (+0.16%) As of 05/30/2025 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
